Fauziya, A Gupta, A Nadaf, S Ahmad,
N Hasan… - Medical Oncology, 2023 - Springer
Dasatinib is the 2nd generation TKI (Tyrosine Kinase Inhibitor) having the potential to treat
numerous forms of leukemic and cancer patients and it is 300 times more potent than …